<DOC>
	<DOCNO>NCT02202564</DOCNO>
	<brief_summary>HCC patient tumor &gt; 5 cm diameter , regardless involvement intrahepatic extrahepatic portal branch participate study . Patients randomize allocate liver transplantation ( LT ) group LT plus ADV-TK therapy group . All patient receive orthotopic liver transplantation ; LT plus ADV-TK group , ADV-TK therapy deliver patient twice .</brief_summary>
	<brief_title>Preliminary Results Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome Liver Transplantation Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>18ï½ž70 year age ( Male Female ) . Clinical diagnosis advance hepatocellular carcinoma could accept liver transplantation Patients unresectable HCC &gt; 5 cm metastasis lung bone eligible participate study . Tumor involvement intrahepatic extrahepatic portal branch consider exclusion criterion . No prior chemotherapy , radiation therapy , target therapy kind biological treatment within 4 week . Provide write informed consent Metastasis lungs bone Invasion main vescular . Contraindications liver transplantation Contraindications operation organ system Hypersensitivity adenovirus , GCV similar drug Accept clinical trial drug Immunological deficit Active pregnancy Unable unwilling sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>adenovirus-thymidine kinase</keyword>
	<keyword>gene therapy</keyword>
</DOC>